Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients

British Journal of Cancer

Volumn 109, Issue 10, 2013, Pages 2629-2635

  Jie, H B ^a   Gildener Leapman, N ^a   Li, J ^a,b   Srivastava, R M ^a   Gibson, S P ^a   Whiteside, T L ^a   Ferris, R L ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Tsinghua University   (China)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; CD39 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CD25+ T LYMPHOCYTE; CELL FUNCTION; CELL ISOLATION; CLINICAL ARTICLE; COMPARATIVE STUDY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; APYRASE; CARCINOMA, SQUAMOUS CELL; CTLA-4 ANTIGEN; CYTOKINES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY;

EID: 84887832812     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.645     Document Type: Article

References (28)

1. Bastid J, Cottalorda-Regairaz A, Alberici G, Bonnefoy N, Eliaou JF, Bensussan A (2013) ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene 32: 1743-1751.
2. Camisaschi C, Casati C, Rini F, Perego M, De Filippo A, Triebel F, Parmiani G, Belli F, Rivoltini L, Castelli C (2010) LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumour sites. J Immunol 184: 6545-6551.
3. Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, Hall J, Sun CM, Belkaid Y, Powrie F (2007) A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 204: 1757-1764.
4. Darrasse-Jeze G, Bergot AS, Durgeau A, Billiard F, Salomon BL, Cohen JL, Bellier B, Podsypanina K, Klatzmann D (2009) Tumour emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumours in mice. J Clin Invest 119: 2648-2662.
5. deLeeuw RJ, Kost SE, Kakal JA, Nelson BH (2008) The prognostic value of FoxP3+ tumour-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 18: 3022-3029.
6. Fife BT, Bluestone JA (2008) Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 224: 166-182.
7. Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236: 219-242.
8. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH (2009) PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206: 3015-3029.
9. Hiraoka N, Onozato K, Kosuge T, Hirohashi S (2006) Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12: 5423-5434.
10. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H (2003) Increased populations of regulatory T cells in peripheral blood and tumour-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9: 4404-4408.
11. Joller N, Peters A, Anderson AC, Kuchroo VK (2012) Immune checkpoints in central nervous system autoimmunity. Immunol Rev 248: 122-139.
12. Lopez-Albaitero A, Mailliard R, Hackman T, Andrade Filho PA, Wang X, Gooding W, Ferrone S, Kalinski P, Ferris RL (2009) Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function. J Immunother 32: 465-473.
13. Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, Ren J, Lang S, Jackson EK, Gorelik E, Whiteside TL (2010) Generation and accumulation of immunosuppressive adenosine by human CD4+ CD25highFOXP3+ regulatory T cells. J Biol Chem 285: 7176-7186.
14. Nikolova M, Carriere M, Jenabian MA, Limou S, Younas M, Kok A, Hue S, Seddiki N, Hulin A, Delaneau O, Schuitemaker H, Herbeck JT, Mullins JI, Muhtarova M, Bensussan A, Zagury JF, Lelievre JD, Levy Y (2011) CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog 7: e1002110.
15. Oida T, Xu L, Weiner HL, Kitani A, Strober W (2006) TGF-beta-mediated suppression by CD4+CD25+ T cells is facilitated by CTLA-4 signaling. J Immunol 177: 2331-2339.
16. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264.
17. Perez N, Karumuthil-Melethil S, Li R, Prabhakar BS, Holterman MJ, Vasu C (2008) Preferential costimulation by CD80 results in IL-10-dependent TGF-beta1(+)-adaptive regulatory T cell generation. J Immunol 180: 6566-6576.
18. Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A, Balsamo M, Conte R, Benelli R, Minghelli S, Solari N, Gualco M, Queirolo P, Moretta L, Mingari MC (2012) Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 72: 1407-1415.
19. Qiao G, Yang L, Li Z, Ying H, Hassen Y, Yin F, Zhang J (2012) Program death-1 regulates peripheral T cell tolerance via an anergy-independent mechanism. Clin Immunol 143: 128-133.
20. Sainz-Perez A, Lim A, Lemercier B, Leclerc C (2012) The T-cell receptor repertoire of tumour-infiltrating regulatory T lymphocytes is skewed toward public sequences. Cancer Res 72: 3557-3569.
21. Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL (2005) Characteristics of CD4+ CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 92: 913-920.
22. Schuler PJ, Schilling B, Harasymczuk M, Hoffmann TK, Johnson J, Lang S, Whiteside TL (2012) Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients. Eur J Immunol 42: 1876-1885.
23. Strauss L, Bergmann C, Gooding W, Johnson JT, Whiteside TL (2007) The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13: 6301-6311.
24. Sun CM, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR, Belkaid Y (2007) Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med 204: 1775-1785.
25. Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Bluestone JA (2004) Distinct roles of CTLA-4 and TGF-beta in CD4+ CD25+ regulatory T cell function. Eur J Immunol 34: 2996-3005.
26. Walker LS, Sansom DM (2011) The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 11: 852-863.
27. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322: 271-275.
28. Zheng Y, Manzotti CN, Burke F, Dussably L, Qureshi O, Walker LS, Sansom DM (2008) Acquisition of suppressive function by activated human CD4+ CD25-T cells is associated with the expression of CTLA-4 not FoxP3. J Immunol 181: 1683-1691.